论文部分内容阅读
0引言肺癌是世界范围内死亡率较高的恶性肿瘤之一,随着临床观察的报道增加,证实以铂类为主的联合化疗对肺癌的疗效达到了一个平台期。为突破这个瓶颈,一类针对肺癌特定的遗传表型,影响特定的分子信号途径的药物逐渐得到发展。当前临床使用和发展的肺癌分子靶向治疗药物,本文就其目前的进展和存在的问题加以阐述。
0 Introduction Lung cancer is one of the most highly malignant cancers in the world. With the increase of clinical observations, it is confirmed that the platinum-based combination chemotherapy has achieved a plateau effect on lung cancer. To break this bottleneck, a class of drugs that target specific lung cancer-specific genetic phenotypes that affect specific molecular signaling pathways are progressively evolving. The current clinical use and development of molecular targeted therapy of lung cancer drugs, this paper on its current progress and existing problems to be elaborated.